Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Abstract

Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.

COI Statement

GMarc received research funds from AbbVie, Astellas, AstraZeneca, Daiichi Sankyo, Pfizer, and Syros and was a consultant or was included in the speaker's bureau for AbbVie, Astellas, AstraZeneca, Immunogen, Janssen, Menarini/Stemline, Pfizer, Ryvu, Servier, Syros, and Takeda. FL received research funds from Pfizer and Alexion and is a consultant from Sobi, Roche, AbbVie, Amgen, and Novartis. MR was a consultant or was included in the speaker's bureau for Novartis, Gentili, Blueprint, and Jazz. GMartinelli is a consultant for AbbVie Inc., Celgene, Roche, Janssen, Astellas, Pfizer, and Incyte. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.

References:

Todisco E., Papayannidis C., Fracchiolla N., et al., “AVALON: The Italian Cohort Study on Real‐Life Efficacy of Hypomethylating Agents Plus Venetoclax in Newly Diagnosed or Relapsed/Refractory Patients With Acute Myeloid Leukemia,” Cancer 129, no. 7 (2023): 992–1004, 10.1002/CNCR.34608.
Ferrara F., Barosi G., Venditti A., et al., “Consensus‐Based Definition of Unfitness to Intensive and Non‐Intensive Chemotherapy in Acute Myeloid Leukemia: A Project of SIE, SIES and GITMO Group on a New Tool for Therapy Decision Making,” Leukemia 27, no. 5 (2013): 997–999, 10.1038/LEU.2012.303.
Apolito V., Arrigo G., Vasseur L., et al., “Validation of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality and Survival in Acute Myeloid Leukaemia Patients Treated With Hypomethylating Agents and Venetoclax,” British Journal of Haematology 203, no. 4 (2023): e98–e101, 10.1111/BJH.19022.
Döhner H., DiNardo C. D., Wei A. H., et al., “Genetic Risk Classification for Adults With AML Receiving Less‐Intensive Therapies: The 2024 ELN Recommendations,” Blood 144 (2024): 2169–2173, 10.1182/BLOOD.2024025409.
Bataller A., Bazinet A., DiNardo C. D., et al., “Prognostic Risk Signature in Patients With Acute Myeloid Leukemia Treated With Hypomethylating Agents and Venetoclax,” Blood Advances 8 (2023): 927–935, 10.1182/BLOODADVANCES.2023011757.

Article info

Journal issue:

Volume: 100
Issue: 4

Doi:

10.1002/ajh.27591

More resources:

Ovid Technologies, Inc.

Full Text Sources

Paid

PubMed Central

Full Text Sources

Free resource

Wiley

Full Text Sources

Paid

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Abstract

Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.

COI Statement

References:

Todisco E., Papayannidis C., Fracchiolla N., et al., “AVALON: The Italian Cohort Study on Real‐Life Efficacy of Hypomethylating Agents Plus Venetoclax in Newly Diagnosed or Relapsed/Refractory Patients With Acute Myeloid Leukemia,” Cancer 129, no. 7 (2023): 992–1004, 10.1002/CNCR.34608.
Ferrara F., Barosi G., Venditti A., et al., “Consensus‐Based Definition of Unfitness to Intensive and Non‐Intensive Chemotherapy in Acute Myeloid Leukemia: A Project of SIE, SIES and GITMO Group on a New Tool for Therapy Decision Making,” Leukemia 27, no. 5 (2013): 997–999, 10.1038/LEU.2012.303.
Apolito V., Arrigo G., Vasseur L., et al., “Validation of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality and Survival in Acute Myeloid Leukaemia Patients Treated With Hypomethylating Agents and Venetoclax,” British Journal of Haematology 203, no. 4 (2023): e98–e101, 10.1111/BJH.19022.
Döhner H., DiNardo C. D., Wei A. H., et al., “Genetic Risk Classification for Adults With AML Receiving Less‐Intensive Therapies: The 2024 ELN Recommendations,” Blood 144 (2024): 2169–2173, 10.1182/BLOOD.2024025409.
Bataller A., Bazinet A., DiNardo C. D., et al., “Prognostic Risk Signature in Patients With Acute Myeloid Leukemia Treated With Hypomethylating Agents and Venetoclax,” Blood Advances 8 (2023): 927–935, 10.1182/BLOODADVANCES.2023011757.